Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer
Clinical trial NCT01912963 · TERMINATED
Trial details
- NCT number
- NCT01912963
- Sponsor
- Dana-Farber Cancer Institute
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2013-09-01
- Primary completion
- 2016-12-01
- Enrollment
- 32
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.